#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	147	16254	16S	1529	1529	100.0	16S.l6.c17.ctg.1	2618	752.6	1	SNP	n	C1184T	0	.	.	1184	1184	C	1806	1806	C	979	C,T	977,1	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	147	16254	16S	1529	1529	100.0	16S.l6.c17.ctg.1	2618	752.6	0	HET	.	.	.	C611T,G	.	611	611	C	1233	1233	C	1010	C,T,G	487,520,2	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	26880	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3999	837.7	0	.	n	.	0	T695C	SNP	695	695	T	1268	1268	C	1014	C,A,G	1010,3,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	26880	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3999	837.7	0	.	n	.	0	G1337A	SNP	1337	1337	G	1910	1910	A	1114	A,C,T,G	1110,2,1,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	26880	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3999	837.7	0	.	n	.	0	T1971C	SNP	1971	1971	T	2544	2544	C	913	C,A,T,G	909,2,1,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	26880	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3999	837.7	1	SNP	n	C2597T	1	C2597T	SNP	2597	2597	C	3170	3170	T	914	T	914	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	26880	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3999	837.7	1	SNP	n	A2045G	0	.	.	2045	2045	A	2618	2618	A	811	A,T	810,1	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
folP.WHO_P_01364c	folP.WHO_P_01364c	1	1	27	2366	folP	852	852	100.0	folP.l15.c4.ctg.1	2068	142.7	1	SNP	p	R228S	1	.	.	682	684	AGC	1270	1272	AGC	234;233;230	A;G;C	234;233;230	folP.WHO_P_01364c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5452	gyrA	2751	2751	99.85	gyrA.l6.c4.ctg.1	3780	179.8	1	SNP	p	S91F	0	.	.	271	273	TCC	772	774	TCC	194;192;190	T;C;C,G	194;192;189,1	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5452	gyrA	2751	2751	99.85	gyrA.l6.c4.ctg.1	3780	179.8	1	SNP	p	D95N	0	.	.	283	285	GAC	784	786	GAC	194;194;194	G;A;C	194;194;194	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5452	gyrA	2751	2751	99.85	gyrA.l6.c4.ctg.1	3780	179.8	1	SNP	p	D95G	0	.	.	283	285	GAC	784	786	GAC	194;194;194	G;A;C	194;194;194	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
mtrR.WHO_K_01388	mtrR.WHO_K_01388	1	1	27	2170	mtrR	633	633	100.0	mtrR.l15.c4.ctg.1	1861	145.6	1	SNP	p	G45D	1	.	.	133	135	GAC	760	762	GAC	251;251;250	G;A,C;C	251;250,1;250	mtrR.WHO_K_01388:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	19	1226	mtrR_promoter	250	250	100.0	mtrR_promoter.l15.c4.ctg.1	1488	102.7	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5362	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3362	198.5	1	SNP	p	D86N	0	.	.	256	258	GAC	768	770	GAC	220;220;216	G;A,C;C	220;219,1;216	parC.WHO_P_00203c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5362	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3362	198.5	1	SNP	p	S87W	0	.	.	259	261	AGT	771	773	AGT	215;217;216	A,C;G;T	214,1;217;216	parC.WHO_P_00203c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5362	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3362	198.5	1	SNP	p	S87R	0	.	.	259	261	AGT	771	773	AGT	215;217;216	A,C;G;T	214,1;217;216	parC.WHO_P_00203c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5362	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3362	198.5	1	SNP	p	S87I	0	.	.	259	261	AGT	771	773	AGT	215;217;216	A,C;G;T	214,1;217;216	parC.WHO_P_00203c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5362	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3362	198.5	1	SNP	p	S88P	0	.	.	262	264	TCC	774	776	TCC	218;218;223	T;C;C,T	218;218;222,1	parC.WHO_P_00203c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	4788	parE	1986	1986	100.0	parE.l15.c4.ctg.1	3190	186.9	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1887	1889	GGC	275;273;271	G;G;C	275;273;271	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.2.001	penA.2.001	1	1	27	4244	penA	1749	1749	100.0	penA.l6.c30.ctg.1	2927	180.6	1	SNP	p	A311V	0	.	.	931	933	GCA	1484	1486	GCA	260;259;255	G,T,A;C,A;A,G	258,1,1;258,1;254,1	penA.2.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4244	penA	1749	1749	100.0	penA.l6.c30.ctg.1	2927	180.6	1	SNP	p	I312M	0	.	.	934	936	ATC	1487	1489	ATC	254;251;254	A,C;T,A;C	253,1;250,1;254	penA.2.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4244	penA	1749	1749	100.0	penA.l6.c30.ctg.1	2927	180.6	1	SNP	p	V316T	0	.	.	946	948	GTG	1499	1501	GTG	238;237;236	G;T;G	238;237;236	penA.2.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4244	penA	1749	1749	100.0	penA.l6.c30.ctg.1	2927	180.6	1	SNP	p	V316P	0	.	.	946	948	GTG	1499	1501	GTG	238;237;236	G;T;G	238;237;236	penA.2.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4244	penA	1749	1749	100.0	penA.l6.c30.ctg.1	2927	180.6	1	SNP	p	T484S	0	.	.	1450	1452	ACC	2003	2005	ACC	232;233;233	A,C;C;C	231,1;233;233	penA.2.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4244	penA	1749	1749	100.0	penA.l6.c30.ctg.1	2927	180.6	1	SNP	p	A502P	0	.	.	1504	1506	GCG	2057	2059	GCG	234;236;234	G;C;G,T	234;236;233,1	penA.2.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4244	penA	1749	1749	100.0	penA.l6.c30.ctg.1	2927	180.6	1	SNP	p	A502V	0	.	.	1504	1506	GCG	2057	2059	GCG	234;236;234	G;C;G,T	234;236;233,1	penA.2.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4244	penA	1749	1749	100.0	penA.l6.c30.ctg.1	2927	180.6	1	SNP	p	G543S	0	.	.	1627	1629	GGC	2180	2182	GGC	240;237;235	G,T;G;C	239,1;237;235	penA.2.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4244	penA	1749	1749	100.0	penA.l6.c30.ctg.1	2927	180.6	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2189	2191	GGC	241;241;240	G;G;C	241;241;240	penA.2.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4244	penA	1749	1749	100.0	penA.l6.c30.ctg.1	2927	180.6	1	SNP	p	P552S	0	.	.	1654	1656	CCG	2207	2209	CCG	241;244;242	C,G;C;G	238,3;244;242	penA.2.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	5988	ponA	2397	2397	99.96	ponA.l15.c4.ctg.1	3511	212.6	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2688	porA	1146	1146	99.83	porA.l15.c4.ctg.1	2267	147.5	0	.	p	.	0	M83fs	FSHIFT	247	247	A	770	770	C	175	C	175	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	3060	porB1b	1047	1047	97.04	porB1b.l15.c4.ctg.1	1688	225.2	0	.	p	.	0	G38E	NONSYN	112	114	GGA	583	585	GAA	291;291;291	G;A;A	291;291;291	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	3060	porB1b	1047	1047	97.04	porB1b.l15.c4.ctg.1	1688	225.2	0	.	p	.	0	S46G	NONSYN	136	138	AGC	607	609	GGC	289;287;287	G;G;C	289;286;287	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	3060	porB1b	1047	1047	97.04	porB1b.l15.c4.ctg.1	1688	225.2	0	.	p	.	0	E48G	NONSYN	142	144	GAA	613	615	GGA	293;292;295	G;G,T;A	293;291,1;295	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	3060	porB1b	1047	1047	97.04	porB1b.l15.c4.ctg.1	1688	225.2	0	.	p	.	0	T87A	NONSYN	259	261	ACT	730	732	GCT	249;250;250	G;C;T	249;250;250	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	3060	porB1b	1047	1047	97.04	porB1b.l15.c4.ctg.1	1688	225.2	0	.	p	.	0	T89S	NONSYN	265	267	ACC	736	738	AGC	245;247;245	A;G;C	245;247;245	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	3060	porB1b	1047	1047	97.04	porB1b.l15.c4.ctg.1	1688	225.2	0	.	p	.	0	.	MULTIPLE	358	359	AA	828	829	CG	223;220	C;G	223;220	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	3060	porB1b	1047	1047	97.04	porB1b.l15.c4.ctg.1	1688	225.2	0	.	p	.	0	.	MULTIPLE	361	362	GA	831	833	CAG	221;217;216	C;A,C;G	221;216,1;216	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	3060	porB1b	1047	1047	97.04	porB1b.l15.c4.ctg.1	1688	225.2	0	.	p	.	0	N122K	NONSYN	364	366	AAC	835	837	AAA	212;212;211	A,T,C;A,T;A,C	210,1,1;211,1;210,1	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	3060	porB1b	1047	1047	97.04	porB1b.l15.c4.ctg.1	1688	225.2	0	.	p	.	0	K143E	NONSYN	427	429	AAA	898	900	GAA	256;255;254	G;A;A	256;255;254	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	3060	porB1b	1047	1047	97.04	porB1b.l15.c4.ctg.1	1688	225.2	0	.	p	.	0	V151A	NONSYN	451	453	GTA	922	924	GCA	267;263;265	G;C;A	267;263;265	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	3060	porB1b	1047	1047	97.04	porB1b.l15.c4.ctg.1	1688	225.2	0	.	p	.	0	A215T	NONSYN	643	645	GCT	1114	1116	ACT	266;265;264	A,T;C,T;T	265,1;264,1;264	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	3060	porB1b	1047	1047	97.04	porB1b.l15.c4.ctg.1	1688	225.2	0	.	p	.	0	I218M	NONSYN	652	654	ATA	1123	1125	ATG	263;262;260	A,G,T;T;G,C	261,1,1;262;259,1	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	3060	porB1b	1047	1047	97.04	porB1b.l15.c4.ctg.1	1688	225.2	0	.	p	.	0	T256A	NONSYN	766	768	ACA	1237	1239	GCA	224;225;227	G,T;C;A	223,1;225;227	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	3060	porB1b	1047	1047	97.04	porB1b.l15.c4.ctg.1	1688	225.2	0	.	p	.	0	W257T	NONSYN	769	771	TGG	1240	1242	ACG	227;227;232	A;C,G;G	227;226,1;232	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	3060	porB1b	1047	1047	97.04	porB1b.l15.c4.ctg.1	1688	225.2	0	.	p	.	0	S258G	NONSYN	772	774	AGT	1243	1245	GGG	233;232;227	G;G;G,T	233;232;226,1	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	3060	porB1b	1047	1047	97.04	porB1b.l15.c4.ctg.1	1688	225.2	0	.	p	.	0	A259V	NONSYN	775	777	GCT	1246	1248	GTT	224;225;225	G;T;T	224;225;225	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	3060	porB1b	1047	1047	97.04	porB1b.l15.c4.ctg.1	1688	225.2	0	.	p	.	0	L279V	NONSYN	835	837	TTA	1306	1308	GTA	255;255;256	G,T;T;A	254,1;255;256	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	3060	porB1b	1047	1047	97.04	porB1b.l15.c4.ctg.1	1688	225.2	0	.	p	.	0	S292T	NONSYN	874	876	TCT	1345	1347	ACT	260;256;256	A,T;C;T,C	259,1;256;255,1	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	3060	porB1b	1047	1047	97.04	porB1b.l15.c4.ctg.1	1688	225.2	0	.	p	.	0	H294D	NONSYN	880	882	CAT	1351	1353	GAT	257;258;263	G,C;A;T,C	256,1;258;262,1	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	3060	porB1b	1047	1047	97.04	porB1b.l15.c4.ctg.1	1688	225.2	0	.	p	.	0	Y298H	NONSYN	892	894	TAC	1363	1365	CAC	272;270;272	C;A,C;C	272;269,1;272	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	3060	porB1b	1047	1047	97.04	porB1b.l15.c4.ctg.1	1688	225.2	1	SNP	p	G120K	1	.	.	358	360	AAG	828	830	CGG	223;220;218	C;G;G,T	223;220;217,1	porB1b.WHO_L_01891c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	3060	porB1b	1047	1047	97.04	porB1b.l15.c4.ctg.1	1688	225.2	1	SNP	p	A121D	1	.	.	361	363	GAC	831	834	CGC	221;216;215	C;G;C	221;216;215	porB1b.WHO_L_01891c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	3060	porB1b	1047	1047	97.04	porB1b.l15.c4.ctg.1	1688	225.2	1	SNP	p	D121N	0	.	.	361	363	GAC	831	834	CGC	221;216;215	C;G;C	221;216;215	porB1b.WHO_L_01891c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	10340	rpoB	4179	4179	100.0	rpoB.l15.c4.ctg.1	5249	245.6	1	SNP	p	H553N	1	.	.	1657	1659	AAT	2178	2180	AAT	263;262;261	A;A,T;T	263;261,1;261	rpoB.WHO_M_02157:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1604	rpsJ	312	312	100.0	rpsJ.l6.c4.ctg.1	1503	132.8	1	SNP	p	V57M	1	.	.	169	171	ATG	796	798	ATG	265;269;267	A;T;G,T	265;269;266,1	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
